ReviewFEBS open bio2026
Directed evolution of enzymes at the crossroads of tradition and innovation.
Review in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Directed evolution has become a central methodology for engineering proteins with improved or entirely new functions, enabling applications across biotechnology, medicine, and synthetic chemistry. By iteratively coupling genetic diversification with screening or selection, directed evolution allows functional optimization even when detailed structural or mechanistic knowledge is unavailable. While display-based selection platforms have enabled the efficient evolution of binders from extremely large libraries, enzyme evolution relies primarily on quantitative screening strategies that preserve genotype-phenotype linkage, often through compartmentalization. This review focuses primarily on enzyme directed evolution, using binder evolution as a comparative reference point to highlight key methodological differences and parallel advances. Major technological advances-including in vitro emulsions, droplet microfluidics, ultrahigh-throughput sorting, genetically encoded biosensors, and alternative detection modalities-have dramatically expanded screening capacity and analytical resolution. We also discuss why stability remains a central constraint on evolvability, why assay design continues to limit translational relevance, and how failures such as surrogate-substrate bias, droplet leakage, tracking errors, and overfitted machine-learning models can misdirect campaigns. By integrating classical strategies with emerging continuous and data-driven approaches, enzyme directed evolution is moving toward more predictive, automated, and industrially translatable workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.